¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Other complications specific to multiple gestation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple division
    º¹Çպп­
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
  • multiple endocrine adenomatosis
    ´Ù¹ß¼º³»ºÐºñ»ùÁ¾Áõ
  • multiple endocrine neoplasia
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç
  • multiple endocrine neoplasia 1
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç1Çü
  • multiple endocrine neoplasia 2
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç2Çü
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • multiple epiphyseal dysplasia
    ¹µ»À³¡Çü¼ºÀÌ»ó, ´Ù¹ß°ñ´ÜÇü¼ºÀÌ»ó
  • multiple excitation
    ´Ù¹ßÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple field irradiation
    ¿©·¯¿µ¿ªÁ¶»ç
  • multiple fission
    ¹µºÐ¿­, ´ÙÁߺп­
  • multiple fracture
    ´Ù¹ß°ñÀý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple deformity
    º¹ÇÕ±âÇü
  • multiple division
    º¹Çպп­
  • multiple dysplasia
    ¹µÇü¼ºÀå¾Ö
  • multiple personality disorder
    ´ÙÁßÀΰÝÀå¾Ö
  • hereditary multiple exostosis
    À¯Àü´Ù¹ß»Àµ¹ÃâÁõ
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
  • multiple epitheliomatosis
    ´Ù¹ß»óÇÇÁ¾Áõ
  • multiple excitation
    ¹Ýº¹ÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple fission
    ¹µºÐ¿­, ´Ù¼öºÐ¿­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple sclerotic gait
    ´Ù¹ß°æÈ­Áõ°ÉÀ½
  • multiple infection
    ¿©·¯¹ø°¨¿°
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • polyembryonic gestation
    ¹µ¹èÀÚÀÓ½Å
  • SDA= specific dynamic action
    ƯÀ̵¿Àû ÀÛ¿ë.
  • age specific death rate
    ¿¬·Éº° »ç¸Á·ü
  • antigen, species-specific
    Á¾Æ¯ÀÌÇ׿ø
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group specific C carbohydrate
    ±ºÆ¯ÀÌ C´Ù´çü.
  • group-specific
    ±ºÆ¯ÀÌÀÇ
  • group-specific C carbohydrate
    ±ºÆ¯ÀÌ C ź¼öÈ­¹°
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immunity, specific
    ƯÀ̸鿪
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gestation period
    ÀӽűⰣ(¡­Ñ¢Êà).
  • gestation sac
    ¹æ»ç Àӽų¶(ìôããÒ¥).
  • gestation, anembryonic
    ¹«Å¾Ƽº ÀӽŠ(Ùí÷Ãä®àõ ìõãã)
  • late gestation
    ÀÓ½ÅÈıâ(ìôããý­Ñ¢).
  • monoembryonic gestation
    Ȭ¹èÀÚÀÓ½Å
  • polyembryonic gestation
    ¹µ¹èÀÚÀÓ½Å
  • age specific death rate
    ¿¬·Éº° »ç¸Á·ü
  • antigen, species-specific
    Á¾Æ¯ÀÌÇ׿ø
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú.
  • bulk specific gravity
    ¿ëÀûºñÁß(é»îÝÝïñì)
  • donor-specific phage
    °ø¿©±ÕƯÀÌÆÄÁö
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • site-specific inversion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ¿ªÀ§(æ½êÈ)
  • site-specific recombinstion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ÀçÁ¶ÇÕ(î¢ðÚùê)
  • specific acid-base catalysis
    ƯÀÌ »ê.¿°±â Ã˸Å(÷åì¶ß«ç¤ÐñõºØÚ)
  • specific activity
    ºñȰ¼º(ÝïüÀàõ)
  • specific adsorption
    ¼±ÅÃÈíÂø(àÔ÷Éýåó·)
  • specific dynamic action
    ƯÀÌ µ¿Àû ÀÛ¿ë(÷åì¶ÔÑîÜíÂéÄ)
  • specific extinction coefficient
    ºñÈí±¤ °è¼ö(ÝïýåÎÃÌõâ¦)
  • specific gravity
    ºñÁß(Ýïñì)
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
  • specific heat
    ºñ¿­(Ýïæð)
  • specific immune suppression
    ƯÀÌ ¸é¿ª¾ï¾Ð(÷åì¶Øóæ¹åääâ)
  • specific immunity
    ƯÀ̸鿪(÷åì¶Øóæ¹)
  • specific interaction theory
    ƯÀÌ »óÈ£ÀÛ¿ëÀÌ·Ð(÷åì¶ßÓû»íÂéÄ×âÖå)
  • specific ionization
    ºñ(Ýï) ÀÌ¿ÂÈ­(ûù)
  • specific radioactivity
    ºñ¹æ»ç´É(ÝïÛ¯ÞÒÒö)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple myeloma
    ´Ù¹ß¼º°ñ¼öÁ¾
  • multiple overlapping thin slab acquisition [=MOTSA]
    ´ÙÁßÁߺ¹¼¼ÆíÆÇȹµæ
  • multiple polyp
    ´Ù¹ß¼ºÆú¸³
  • multiple sclerosis
    ´Ù¹ß¼º°æÈ­Áõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
AMI Acute Myocardial Infarction
  - Complications(Cx)
    1. Early ...
CoA Coarctation of Aorta
  - Complications
    1. Severe Hypertensi...
SAH Sub-Arachnoid Hemorrhage; (³ú)ÁöÁÖ¸·ÇÏÃâÇ÷
  ? Complications
    1. Is...
AS-SCORE age, stage of disease, physiological system involved, complications, response to therapy
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
dGA days gestation
GW gestation
wg week of gestation
DRO Differential Reinforcement of Other Behaviour
MOTT Mycobacteria Other Than Tuberculosis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • non-specific response
    ºñƯÀ̼º ¹ÝÀÀ
  • specific
    ƯÀÌÇÑ, Á¾ÀÇ, Á¾Á·ÀÇ, ƯÀÌÀÇ, ƯÀ̼ºÀÇ, ƯÀÌÀûÀÎ
    1. ÇÑ Á¾·ùÀÇ ¹Ì»ý¹°¿¡ ÀÇÇØ¼­ »ê»ýµÇ´Â. 2. Ư¼ö¼ºÀÇ. Àû¿ë, È¿°ú µîÀÌ Æ¯Á¤ÇÑ ±¸Á¶, ±â´É µî¿¡ ÇÑÁ¤µÈ. 3. ƯȿÀÇ ¾î¶² ƯÁ¤ Áúȯ¿¡ ´ëÇØ¼­ Ưº°È÷ À¯È¿ÇÑ ÀǾàǰ. 4. ¸é¿ªÇп¡ À־ ´ëÀÀÇÏ´Â Ç×ü¿¡ ´ëÇÑ Ç׿øÀÇ Æ¯º°ÇÑ Ä£È­¼º¿¡ °üÇÑ.
  • specific activity
    ƯÀÌ È°¼º, ƯÀÌ È°¼ºµµ, ºñȰ¼º, ºñȰ¼ºµµ
  • specific alopecia
    Ư¼ö Å»¸ðÁõ
  • specific congenital heart defects
    °³º° º´¼Ò
  • specific criteria
    ƯÀÌÇÑ ±âÁØ
  • specific dentist-patient relationship
    µ¶Æ¯ÇÑ Ä¡°ú ÀÇ»ç-ȯÀÚ °ü°è
  • specific energy of sense
    Ư¼ö °¨°¢ ¿¡³ÊÁö
  • specific gamma emission
    Ư¼ö °¨¸¶ ¹æÃâ
  • specific gravity test
    ºñÁß ½ÃÇè
  • specific humoral immunity
    ƯÀ̼º ü¾× ¸é¿ª
  • specific inflammation
    ƯÀ̼º ¿°Áõ
  • specific membrane receptor
    ƯÁ¤ ¸· ¼ö¿ë±â
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific receptor
    ƯÀÌ ¼ö¿ëü, ƯÀÌ ¼ö¿ë±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
intraoperative complications Disorders affecting patients during surgery. They may or may not be related to the disease for which the surgery is done. They may or may not be direct results of the surgery.
(12 Dec 1998)
labour complications <obstetrics> Medical problems associated with labour including cephalopelvic disproportion, haemorrhage, foetal distress, or other disorders.
(12 Dec 1998)
abortion, multiple Couples who have had 2 or more miscarriages (spontaneous abortions) have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages.
(12 Dec 1998)
advanced multiple-beam equalization radiography A variant of scanning equalization radiography using several X-ray beams.
(05 Mar 2000)
amyloidosis of multiple myeloma Foci of amyloidosis in mesenchymal tissues of some persons with multiple myeloma; no direct relation between amyloid and Bence Jones protein is conclusively known.
(05 Mar 2000)
cancer, multiple myeloma A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (excess calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly Cancer, non-Hodgkin's lymphoma: A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
chromosomes in multiple miscarriages Couples who have had more than one miscarriage (spontaneous abortion) have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages.
(12 Dec 1998)
miscarriages, multiple, chromosomes in Couples who have had more than one miscarriage have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages.
(12 Dec 1998)
multiple Manifold, occurring in or affecting various parts of the body at once.
Origin: L. Multiplex
(18 Nov 1997)
multiple alcohol An alcohol containing more than one OH group.
(05 Mar 2000)
multiple amputation Amputation of two or more limbs or parts of limbs performed at the same operation.
(05 Mar 2000)
multiple anchorage Anchorage in which more than one type of resistance unit is utilised.
Synonym: reinforced anchorage.
(05 Mar 2000)
multiple birth offspring The offspring in multiple pregnancies (pregnancy, multiple): twins, triplets, quadruplets, quintuplets, etc.
(12 Dec 1998)
multiple carboxylase deficiency Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase.
(12 Dec 1998)
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • some other time
    ¾ðÁ¨°¡ µý³¯¿¡(=some other day)
  • t'other
    ¶Ç Çϳª
  • A.N. Other
    ÀÍ¸í¾¾;¼±¼ö ¹ÌÁ¤
  • other
    µý;´Ù¸¥;´ÙÀ½ÀÇ;³ª¸ÓÁöÀÇ;every ~ Çϳª°É·¯;none ~ than ´Ù¸§ ¾Æ´Ñ;the ~ day(night)ÀÏÀü(¿äÀü³¯ ¹ã)¿¡;the ~ party »ó´ë¹æ;the ~ side (¹Ì±¹¿¡¼­ º») À¯·´;the ~ world ³»¼¼;Àú½Â
  • other
    ±×·¸Áö ¾Ê°í;µý ¹æ¹ýÀ¸·Î
  • other
    µý °Í(»ç¶÷);´Ù¸¥ Çϳª;³ª¸ÓÁö °Í;of all ~s ¸ðµç °Í(»ç¶÷)Áß¿¡¼­ ƯÈ÷;some ... or ~ ¹«¾ð(´©±º,¾îµò)°¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á